TCM
AVTX icon

TCG Crossover Management’s Avalo Therapeutics AVTX Stock Holding History

TCG Crossover Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11M Buy
738,383
+255,383
+53% +$3.99M 0.32% 40
2025
Q4 		$8.77M Hold
483,000
– – 0.29% 37
2025
Q3 		$6.14M Hold
483,000
– – 0.3% 36
2025
Q2 		$2.41M Hold
483,000
– – 0.28% 34
2025
Q1 		$3.87M Hold
483,000
– – 0.53% 33
2024
Q4 		$3.59M Hold
483,000
– – 0.35% 36
2024
Q3 		$4.59M Buy
+483,000
New +$4.98M 0.39% 32

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TCG Crossover Management's AVTX Position: Q1 2026 in Review

TCG Crossover Management increased its Avalo Therapeutics (AVTX) stake by 53% in Q1 2026, buying an estimated $3.99M and bringing the position to 738,383 shares worth $11M. The position accounts for 0.32% of the portfolio, ranked #40.

TCG Crossover Management first reported a position in AVTX in Q3 2024 and has held it in 7 quarters since. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • TCG Crossover Management held 738,383 shares of Avalo Therapeutics worth $11M as of Q1 2026.
  • TCG Crossover Management bought 255,383 Avalo Therapeutics shares in Q1 2026, an estimated $3.99M.
  • Avalo Therapeutics made up 0.32% of TCG Crossover Management's portfolio in Q1 2026, its #40 holding.
  • TCG Crossover Management first reported a position in Avalo Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on TCG Crossover Management's 13F filing for Q1 2026, filed 15 May 2026.